Relay Therapeutics Inc Dossier - Source-backed chat

Relay Therapeutics Inc

RLAYNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.45

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $18.49Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $4.1B

Enterprise Value $3.9B

Shares Outstanding 192.7M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Relay Therapeutics is transitioning from a platform-technology showcase to a late-stage clinical powerhouse, centered on its lead precision oncology asset, zovegalisib (RLY-2608). Zovegalisib is the first pan-mutant selective PI3Kα inhibitor to enter clinical development, addressing a massive market of approximately 140,000 HR+/HER2- breast cancer patients and 170,000 vascular anomaly patients in the US. Recent clinical data has validated the asset's best-in-class potential, showing an 11.1-month median PFS in heavily pretreated breast cancer patients and a 60% volumetric response rate in rare vascular anomalies. Backed by a robust cash position of $642.1 million as of Q1 2026, further bolstered by a $275 million public offering in May 2026, Relay possesses a secure runway extending into 2029. This financial cushion insulates the company from near-term capital market volatility, allowing it to aggressively advance its Phase 3 ReDiscover-2 trial and prepare for a frontline Phase 3 triplet study in early 2027.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets13 analysts · as of 18 Aug 2026

Low · most bearish analyst$20.00

Mean target$27.00

High · most bullish analyst$32.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$20.00

Zovegalisib fails to meet its primary progression-free survival endpoints in the Phase 3 ReDiscover-2 trial, or exhibits unexpected late-stage safety signals that limit chronic dosing. Competitors with selective PI3Kα or FGFR2 programs capture the market first, severely compressing Relay's commercial potential. High R&D burn quickly depletes the cash reserves, forcing highly dilutive capital raises at depressed valuations.

Base CaseCentral scenario

$27.00

Matches the consensus mean

Zovegalisib successfully completes Phase 3 development in second-line HR+/HER2- metastatic breast cancer, meeting its primary endpoints and securing FDA approval. The rare vascular anomalies program advances steadily into pivotal trials, confirming its strong early efficacy profile. Relay initiates its frontline Phase 3 triplet trial in early 2027 as planned, maintaining a disciplined cash burn rate that preserves its runway into late 2028/2029.

Bull CaseUpside scenario

$32.00

Zovegalisib achieves outstanding Phase 3 results in breast cancer, demonstrating superior safety and efficacy over orthosteric inhibitors by avoiding wild-type PI3Kα toxicities like hyperinsulinemia. Simultaneously, rapid regulatory approval is secured for PIK3CA-driven vascular anomalies, establishing a highly profitable, multi-indication franchise. The Dynamo platform continues to yield high-value candidates, leading to lucrative biopharma partnerships.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Zovegalisib is a highly differentiated, first-in-class allosteric pan-mutant selective PI3Kα inhibitor designed to avoid wild-type toxicities.
Strong clinical validation with an 11.1-month median PFS in CDK4/6-experienced breast cancer and a 60% volumetric response rate in vascular anomalies.
Robust balance sheet with $642.1 million in cash as of Q1 2026, plus an additional $275 million raised in May 2026, extending the operational runway into 2029.
Strategic clinical supply agreement with Pfizer to evaluate a promising triplet combination in frontline breast cancer starting in early 2027.

Key Investment Risks

High clinical and regulatory binary risk associated with the ongoing Phase 3 ReDiscover-2 trial.
Intense competition in the PI3Kα and precision oncology space from major pharmaceutical and biotechnology peers.
Substantial operational cash burn typical of late-stage clinical development, which could lead to future shareholder dilution.

Thesis Invalidation Triggers

Failure of zovegalisib to meet primary endpoints in the Phase 3 ReDiscover-2 trial.
Severe safety or tolerability issues emerging in the vascular anomalies or frontline triplet cohorts.
Significant delays in the initiation of the frontline Phase 3 trial planned for early 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.